These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 36203787)

  • 21. Long-Term Effectiveness and Tolerability of Pain Treatment with Tapentadol Prolonged Release.
    Mateos RG; Bernal DS; Morera LMT; Ferri CM; Escobar AE
    Pain Physician; 2021 Jan; 24(1):E75-E85. PubMed ID: 33400440
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single dose analgesic efficacy of tapentadol in postsurgical dental pain: the results of a randomized, double-blind, placebo-controlled study.
    Kleinert R; Lange C; Steup A; Black P; Goldberg J; Desjardins P
    Anesth Analg; 2008 Dec; 107(6):2048-55. PubMed ID: 19020157
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes of the Pediatric Development Plan of Tapentadol.
    Eerdekens M; Radic T; Sohns M; Khalil F; Bulawa B; Elling C
    J Pain Res; 2021; 14():249-261. PubMed ID: 33542654
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of tapentadol in laying hens and its residues in eggs after multiple oral dose administration.
    De Vito V; Owen H; Marzoni M; Kim TW; Poapolathep A; Giorgi M
    Br Poult Sci; 2018 Feb; 59(1):128-133. PubMed ID: 29115161
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of acetaminophen, naproxen, and acetylsalicylic acid on tapentadol pharmacokinetics: results of two randomized, open-label, crossover, drug-drug interaction studies.
    Smit JW; Oh C; Rengelshausen J; Terlinden R; Ravenstijn PG; Wang SS; Upmalis D; Mangold B
    Pharmacotherapy; 2010 Jan; 30(1):25-34. PubMed ID: 20030470
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
    Zhao RK; Cheng G; Tang J; Song J; Peng WX
    Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study.
    Steigerwald I; Müller M; Davies A; Samper D; Sabatowski R; Baron R; Rozenberg S; Szczepanska-Szerej A; Gatti A; Kress HG
    Curr Med Res Opin; 2012 Jun; 28(6):911-36. PubMed ID: 22443293
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the performance of a prior tacrolimus population pharmacokinetic kidney transplant model among adult allogeneic hematopoietic stem cell transplant patients.
    Zhu J; Campagne O; Torrice CD; Flynn G; Miller JA; Patel T; Suzuki O; Ptachcinski JR; Armistead PM; Wiltshire T; Mager DE; Weiner DL; Crona DJ
    Clin Transl Sci; 2021 May; 14(3):908-918. PubMed ID: 33502111
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tapentadol immediate release for the relief of moderate-to-severe acute pain.
    Hartrick CT
    Expert Opin Pharmacother; 2009 Nov; 10(16):2687-96. PubMed ID: 19795998
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An innovative phase I population pharmacokinetic approach to investigate the pharmacokinetics of an intranasal fentanyl spray in healthy subjects.
    Plock N; Facius A; Hartmann L; Baumann S; Nave R
    Int J Clin Pharmacol Ther; 2013 Jun; 51(6):495-508. PubMed ID: 23611571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
    Guo F; Letrent SP; Munster PN; Britten CD; Gelmon K; Tolcher AW; Sharma A
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):97-109. PubMed ID: 17805538
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model-based pediatric dose estimation.
    Rittig S; Baka-Ostrowska M; Tøndel C; Walle JV; Kjaeer B; Passier P; Bosman B; Stroosma O; Tannenbaum S
    J Pediatr Urol; 2020 Feb; 16(1):31.e1-31.e10. PubMed ID: 31787582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic and pharmacodynamic modeling of opioid-induced gastrointestinal side effects in patients receiving tapentadol IR and oxycodone IR.
    Xu XS; Etropolski M; Upmalis D; Okamoto A; Lin R; Nandy P
    Pharm Res; 2012 Sep; 29(9):2555-64. PubMed ID: 22618801
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tapentadol immediate-release for acute postbunionectomy pain: a phase 3, randomized, double-blind, placebo-controlled, parallel-group study in Taiwan.
    Chen YJ; Chiang CC; Huang PJ; Huang J; Karcher K; Li H
    Curr Med Res Opin; 2015 Nov; 31(11):2001-9. PubMed ID: 26293513
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy and tolerability of multiple-dose tapentadol immediate release for the relief of acute pain following orthopedic (bunionectomy) surgery .
    Stegmann JU; Weber H; Steup A; Okamoto A; Upmalis D; Daniels S
    Curr Med Res Opin; 2008 Nov; 24(11):3185-96. PubMed ID: 18851776
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patient considerations in the use of tapentadol for moderate to severe pain.
    Vadivelu N; Huang Y; Mirante B; Jacoby M; Braveman FR; Hines RL; Sinatra R
    Drug Healthc Patient Saf; 2013; 5():151-9. PubMed ID: 23861601
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IMI2-PainCare-BioPain-RCT2 protocol: a randomized, double-blind, placebo-controlled, crossover, multicenter trial in healthy subjects to investigate the effects of lacosamide, pregabalin, and tapentadol on biomarkers of pain processing observed by non-invasive neurophysiological measurements of human spinal cord and brainstem activity.
    Leone C; Di Stefano G; Di Pietro G; Bloms-Funke P; Boesl I; Caspani O; Chapman SC; Finnerup NB; Garcia-Larrea L; Li T; Goetz M; Mouraux A; Pelz B; Pogatzki-Zahn E; Schilder A; Schnetter E; Schubart K; Tracey I; Troconiz IF; Van Niel H; Hernandez JMV; Vincent K; Vollert J; Wanigasekera V; Wittayer M; Phillips KG; Truini A; Treede RD
    Trials; 2022 Sep; 23(1):739. PubMed ID: 36064434
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study.
    Willmann S; Thelen K; Kubitza D; Lensing AWA; Frede M; Coboeken K; Stampfuss J; Burghaus R; Mück W; Lippert J
    Thromb J; 2018; 16():32. PubMed ID: 30534008
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is tapentadol an advance on tramadol?
    Guay DR
    Consult Pharm; 2009 Nov; 24(11):833-40. PubMed ID: 20092221
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial.
    Schwartz S; Etropolski M; Shapiro DY; Okamoto A; Lange R; Haeussler J; Rauschkolb C
    Curr Med Res Opin; 2011 Jan; 27(1):151-62. PubMed ID: 21162697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.